Drug Repurposing (DR) is an alternative to the traditional drug discovery process. It is cost and time effective with high returns and low-risk process that can tackle the increasing need for interventions for varied diseases and new outbreaks. Repurposing of old drugs for other diseases has gained wider attention, as there have been several old drugs approved by the FDA for new diseases. In the global emergency of COVID-19 pandemic, this is one of the strategies implemented in the repurposing of old anti-infective, anti-rheumatic and anti-thrombotic drugs. The goal of the current review is to elaborate the process of DR, its advantages, repurposed drugs for a plethora of disorders, and the evolution of related academic publications. Further, detailed are the computational approaches: literature mining and semantic inference, network-based drug repositioning, signature matching, retrospective clinical analysis, molecular docking and experimental phenotypic screening. We discuss the legal and economic potential barriers in DR, existent collaborative models and recommendations for overcoming these hurdles and leveraging the complete potential of DR in finding new indications. Read more about the article here:https://bit.ly/3yMobGT
Extend the scope and visibility of your research by creating an animated abstract.
Bentham Science has collaborated with Focus Medica, one of the world’s largest publishers of expert animated atlases and videos in medicine and science.
An animated abstract will help summarise the essential discoveries/ key findings of your published research or review article. Each professionally produced full-coloured animated abstract in video format (length 3 – 5 minutes) is accompanied by an English spoken or foreign language commentary. The animated abstract will be published online along with the published article.
The payment for an animated abstract will be US$ 1400 for English language, and US$ 1900 for Foreign language articles. Initially, an advance payment of US$ 500 of the total payment will be payable to the Publisher to start work on the Animated Abstract, US$ 900 (English language) or US$ 1400 (Foreign language) will be payable on completion of the Animated Abstract.
Authors who opt for the “Animated Abstract” option and also wish to have their article made available on an “Open Access Plus” basis will be entitled to a 50% discount only on the Animated Abstract fee and, in addition, pay the normal Open Access Plus fee.
Authors will be asked whether they wish to opt-in for this paid service, and if not, the article will be published as normal. Animated abstracts are available as open access (free viewing) for maximum visibility and awareness to your readers at anytime, anywhere. The animated abstracts are licensed under the terms of the Creative Commons Attribution – NonCommercial-NoDerivatives 4.0 International Public License (CC BY-NC-ND 4.0) https://creativecommons.org/licenses/by-nc-nd/4.0/.
One of our animated abstracts can be viewed below:
Current Advances in Developing Inhibitors of Bacterial Multidrug Efflux Pumps
Author(s): Hannah Y. Mahmood, Shirin Jamshidi, J. Mark Sutton, Khondaker M. Rahman.
Antimicrobial resistance represents a significant challenge to future healthcare provision.An acronym ESKAPEE has been derived from the names of the organisms recognised as the major threats although there are a number of other organisms, notably Neisseria gonorrhoeae, that have become equally challenging to treat in the clinic. These pathogens are characterised by the ability to rapidly develop and/or acquire resistance mechanisms in response to exposure to different antimicrobial agents. A key part of the armoury of these pathogens is a series of efflux pumps, which effectively exclude or reduce the intracellular concentration of a large number of antibiotics, making the pathogens significantly more resistant. These efflux pumps are the topic of considerable interest, both from the perspective of basic understanding of efflux pump function, and its role in drug resistance but also as targets for the development of novel adjunct therapies. The necessity to overcome antimicrobial resistance has encouraged investigations into the characterisation of resistance-modifying efflux pump inhibitors to block the mechanisms of drug extrusion, thereby restoring antibacterial susceptibility and returning existing antibiotics into the clinic. A greater understanding of drug recognition and transport by multidrug efflux pumps is needed to develop clinically useful inhibitors, given the breadth of molecules that can be effluxed by these systems. This review discusses different bacterial EPIs originating from both natural source and chemical synthesis and examines the challenges to designing successful EPIs that can be useful against multidrug resistant bacteria. To know more about our Animated Abstract, please visit: http://www.eurekaselect.com/video.html